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Neurodegenerative Diseases and 
Their Therapeutic Approaches
Farhin Patel and Palash Mandal
Abstract
Alzheimer’s disease and Parkinson’s disease are characterized as a chronic and 
progressive neurodegenerative disorder and are manifested by the loss of neurons 
within the brain and/or spinal cord. In the present chapter, we would like to sum-
marize the molecular mechanism focusing on metabolic modification associated with 
neurodegenerative diseases or heritable genetic disorders. The identification of the 
exact molecular mechanisms involved in these diseases would facilitate the discovery 
of earlier pathophysiological markers along with substantial therapies, which may 
consist (of) mitochondria-targeted antioxidant therapy, mitochondrial dynamics 
modulators, epigenetic modulators, and neural stem cell therapy. Therefore, all these 
therapies may hold particular assurance as influential neuroprotective therapies in the 
treatment of neurodegenerative diseases.
Keywords: neurons, mitochondria-targeted antioxidants, mitochondrial dynamics, 
epigenetic regulations, stem cell, neurodegenerative diseases
1. Introduction
1.1 What are neurons?
Neurons or nerve cells are the functional unit of the brain and nervous system, 
and they produce electrical signals known as action potentials. Action potentials 
permit them to speedily pass on the details over long distances. Their connections 
define who we are as a person. The creation of new neurons in the brain is known as 
neurogenesis [1].
1.2 Anatomy of a neuron
Different types of neurons may differ in a number of ways, but they all include 
three distinct regions with differing functions, that is, the cell body (soma), fol-
lowed by the dendrites, the axons, and the connected axon terminals (Figure 1).
a. Cell body: It is the place of biogenesis of almost all neuronal proteins and 
membranes. It contains a nucleus.
b. Dendrites: The extensions of neurons that receive signals and conduct them 
toward the cell body (soma) are known as dendrites.
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c. Axon (nerve fiber): The extensions of neurons that conduct the signals away 
from the cell body to the other nerve cells or neuron are known as axons.
d. Axon terminal (end-plate): The end part or terminal part of axons that makes 
a synaptic contact with other nerve cells is known as an axon terminal. It is 
responsible for the initiation of transmission of nerve impulse to another nerve 
cell [2].
1.3 Functions of neurons
a. Conduction and transmission of nerve impulses
b. Initiation and conduction of action potential
c. Synaptic transmission [3]
1.4 How neurons transmit information throughout the body?
Neurons converse with other neurons through axons and dendrites. When a 
neuron receives information from another neuron, it transmits an electrical signal 
along the length of the respective axon, known as action potential. At the axon 
terminal, the electrical signal is changed into chemical signal. The axon releases 
chemical messengers called neurotransmitters. The neurotransmitters are released 
into the gap between the axon terminal and the tip of a dendrite (receptor site) of 
a further neuron. The space between the axon terminal and the tip of a dendrite 
is called a synapse. The neurotransmitters travel along the short distance through 
the synaptic gap to the dendrite. The dendrite receives the neurotransmitters and 
translates the chemical signal into electrical signal. This electrical signal travels all 
the way through the neuron, to be converted back into a chemical signal when it 
gets to adjoining neurons [4].
Figure 1. 
Anatomy of neuron.
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2. Neurodegenerative diseases
Etymologically, the word neurodegeneration comprises of “neuro,” which refers 
to neurons, and “degeneration,” which refers to the process of losing structure and/
or function of either tissues or organs [5]. A neurodegenerative disease is consid-
ered as a slow, progressive failure of nerve cells within the central nervous system 
(CNS). This leads to deficits in particular brain functions like learning, movement, 
and cognition generally performed by the CNS (brain and spinal cord).
2.1 Factors associated with neurodegenerative diseases
a. Aberrant protein dynamics with aggregation and degradation of defective 
protein [6]
b. Oxidative stress and reactive oxygen species (ROS) formation
c. Impaired bioenergetics and mitochondrial dysfunction
d. Excessive exposure to metals and pesticides (Figure 2)
2.2 Classification based on molecular defects
a. Trinucleotide repeat diseases: HD, spinal cerebellar atrophy, and myotonic 
dystrophy [7].
b. Prion diseases: Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker 
syndrome, and fetal familial insomnia [8].
Figure 2. 
Factors associated with neurodegenerative diseases.
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c. Synucleinopathies: PD, progressive supranuclear palsy and diffuse Lewy body 
dementia [9].
d. Tauopathies: Corticobasal degeneration, frontotemporal dementia with parkin-
sonism linked to chromosome 1\(FTDP-17), and pick disease [10].
3. Alzheimer’s disease
Alzheimer’s disease (AD) is an irreparable, progressive neurodegenerative disease 
that affects normal brain functioning [11]. It is mainly the general cause of dementia 
[12]. Dementia is a syndrome associated with memory loss and loss of abilities like 
thinking, reasoning, and language skills along with other mental illness [12].
3.1 History
This disease is named after Dr. Alois Alzheimer. He observed some brain tissue 
abnormalities in an old woman who died due to some unusual mental illness. Later, 
he examined her brain and found many abnormal tangled bundles of fibers (called 
as tau tangles, neurofibrillary) and clumps (called as amyloid plaques). That is how 
he found the cause of AD [13].
3.2 Causes
The cause of AD is not clearly understood.
a. Genetic: Nearly, 70% of the cases are related to genetic factors with the involvement 
of many specific genes [14].
1. Autosomal dominant inheritance: Also known as early-onset familial AD 
[15], it occurs due to the mutation in one of the three genes: Presenilin 1, 
presenilin 2, or amyloid precursor protein (APP) [16].
Aβ42: A protein that is the main component of senile plaques, and the levels are 
increased due to mutation in APP and presenilin genes [17].
2. Sporadic Alzheimer’s disease: In this type of AD, genetic and environmental 
factors play a major role.
Example: Inheritance of the epsilon 4 allele of the apolipoprotein E (APOE) [18, 19].
b. Cholinergic hypothesis: The cholinergic hypothesis states that AD is caused 
by the reduced synthesis of neurotransmitter acetylcholine [20].
c. Amyloid hypothesis: The amyloid hypothesis states that AD is caused by the 
deposits of extracellular amyloid beta (Aβ) [21].
d. Tau hypothesis: The tau hypothesis states that AD is caused due to abnormalities 
in tau protein, leading to the disintegration of microtubules in nerve cells [22, 23].
3.3 Molecular mechanism
(a) Proteopathy: AD has been recognized by plaque formation occurring due to 
abnormal folding of amyloid beta (Aβ) protein and tau protein in the nerve cells 
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(brain) leading to the degeneration of nerve cells [24]. The amyloid precursor 
protein (APP) leads to the formation of Aβ. APP plays an important role in neuron-
like developments and post-injury repair mechanism and survival [25, 26]. In AD, 
secreting enzymes like β-secretase and γ-secretase together will break down APP 
into small fragments that penetrate through the neuron membrane [27]. This leads 
to the formation of Aβ fibrils that later cluster together to form senile plaques and 
deposits in the outer side of neurons [28, 29]. Aggregated amyloid fibrils accumu-
lation leads to the disruption of cell’s calcium ion homeostasis, which results in 
apoptosis [30] (Figure 3).
(b) Tauopathy: In AD, there is an abnormal accumulation of tau protein. 
Upon phosphorylation, tau protein stabilizes the microtubules, and it is known as 
microtubule-associated protein. Tau protein undergoes certain chemical changes, 
and becomes hyperphosphorylated. This leads to the formation of neurofibrillary 
tangles upon aggregation with other threads, which results in decaying the neuro-
transport system [31].
3.4 Therapeutic approaches
3.4.1 Mitochondrial-directed therapies
Decline of N-acetyl aspartate and creatine is associated with dementia [32]. 
Supplementation of creatine was found to protect neurons in AD [33]. In hip-
pocampal neurons, administration of creatine defends against glutamate and Aβ 
toxicity in rats [34].
In AD patients, administration of lipoic acid (600 mg/day) [LA - an antioxi-
dant; coenzyme for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase] 
Figure 3. 
Molecular mechanism of AD.
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stabilizes the cognitive measures [35, 36]. Decreased oxidative stress of mitochon-
dria in fibroblasts was found in AD patients due to LA and/or N-acetyl cysteine 
(antioxidant and glutathione precursor) administration [37].
CoQ10 (an antioxidant and cofactor of the electron transport chain) blocks 
apoptosis by inhibiting the permeability transition pore (PTP) of mitochondria 
[38]. Treatment of CoQ10 neutralizes the brain mitochondrial alterations made by 
amyloid-β1–40 [39]. CoQ10 was shown to protect paraquat and rotenone-induced 
mitochondrial dysfunction and neuronal death in SHSY-5Y cells (human neuro-
blastoma cells) and primary rat mesencephalic neurons, [40, 41]. In R6/2 mice, 
combined treatment of CoQ10 and minocycline reduces HTT accumulation, brain 
atrophy, and striatal neuron atrophy [42].
MitoQ (mitochondrial coenzyme Q ) reduces oxidative stress and prevents mito-
chondrial dysfunction [43]. Oral administration of MitoQ (1 mg/kg body weight) 
showed better pharmacokinetics behavior with plasma (Cmax = 33.15 ng/ml and 
Tmax = 1 hr.) in Phase I trial (Antipodean Pharmaceuticals Inc., San Francisco, 
CA).
3.4.2 Stem cell therapy
Neural stem cell therapy provides a potential to neurons derived from stem 
cells to integrate with existing neuronal network of the host brain [44]. In animal 
models, stem cell transplantation elevates the level of acetylcholine, resulting in an 
improved cognitive and memory function. Stem cells secrete neurotrophic factors, 
which modulate neuroplasticity and neurogenesis [45, 46].
Embryonic stem cells (ESCs)-derived neuron progenitor cells (NPCs) when 
transplanted into an amyloid-β injured in vitro model, after 2 weeks of amyloid-β 
injection, showed an increased escape latency when compared with phosphate-
buffered saline-treated controls [47]. It has been reported that ESCs-derived NPCs 
improve memory impairment in AD models [48].
Human induced pluripotent stem cell (iPSC) therapy delivers a possible strategy 
for drug development against AD [49]. Neurons differentiated from iPSCs increase 
the secretion of amyloid-β42 as it is affected by γ-secretase inhibitors [50].
Bone marrow (BM)-derived mesenchymal stem cells (MSCs) play an important 
role in the removal of amyloid-β plaques from the hippocampus [51]. Human MSCs 
promoted amyloid-β clearance and enhanced autophagy and neuronal survival in 
an amyloid-β-treated mouse model [46]. Transplantation of adipose-derived MSCs 
(AMSCs) into AD brain improved the acetylcholine levels along with microglia 
activation and cognitive functions [52, 53]. In a transgenic mouse model, human 
umbilical cord-derived MSCs differentiated themselves into neuron-like cells, and 
these cells when transplanted into an amyloid-β precursor protein (AβPP) and 
PS1 (AβPP/PS1) resulted in improved cognitive function and decreased amyloid β 
deposition [54].
3.4.3 Epigenetic modulators
Histone deacetylases have been linked to AD. Treatment with HDACi (histone 
deacetylase inhibitors) induced dendrite growth, increased the number of syn-
apses, and restored learning and memory deficits in mice with AD [55] (Table 1).
3.4.4 Mitochondrial dynamics modulators
Two recent studies have also shown the protective effects mediated by inhibition 
of mitochondrial fission via Drp1 deficiency on mitochondria and neurons in tau 
and APP transgenic animal models for AD [60, 61].
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4. Parkinson’s disease
Parkinson’s disease (PD) is a progressive, long-term neurodegenerative disorder 
that affects the motor neurons [62]. It is caused by a loss of neurons in the brain 
part known as substantia nigra leading to a reduction in a neurotransmitter called 
dopamine [62].
4.1 History
In 1817, James Parkinson (before known as Jean-Martin Charcot) published 
an essay named “Shaking Palsy” describing six cases of paralysis agitans showing 
certain characteristics of this disease [63, 64].
In 1865, William Sanders termed this disease as Parkinson’s disease [65].
4.2 Causes
The following are the causes of PD:
(a) Environmental factors: Exposure to metals, solvents, and pesticides, or any 
head injuries are considered to be a factor for the onset of PD [66, 67].
(b) Genetics: Few percent of cases are developing this disease due to mutation in 
one specific gene out of several genes related to PD (Table 2).
4.3 Molecular mechanism
The mechanism involved in the development of PD includes various factors 
like the aggregations of misfolded proteins, activation of protein degradation 
HDACi Function References
Sodium butyrate In neuroblastoma cells, it induces phosphorylation of tau 
protein and programmed cell death resulting in restoring 
memory.
[56]
Phenylbutyrate
(4-PBA)
InTg2576 mouse model, 4-PBA restores fear learning and 
rescues dendritic spine losses that are associated with memory 
shortage.
[57]
Suberoylanilide 
hydroxamic acid
In mutant mice model, systemic treatment restores contextual 
memory
[58]
Resveratrol
(activator of class III 
HDAC)
In in vivo and in vitro studies, SIRT1 reduces the 
amyloidogenic processing of APP
[59]
Table 1. 
Histone deacetylase inhibitors and their respective functions in AD.
Name Gene References
Autosomal-dominant PD PARK1/PARK4 SNCA (α-synuclein) [68, 69, 72]
PARK2 Parkin [68, 69, 72]
PARK5 UCHL [68, 69, 72]
PARK8 LRRK2 [68, 69, 72]
Autosomal-recessive PD PARK6 PINK1 [68, 70–72]
PARK7 DJ-1 [68, 70–72]
Table 2. 
Genes involved in PD.
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pathways, mitochondrial damage, and oxidative stress, along with certain gene 
mutations [73–75].
4.3.1 Aggregation of misfolded proteins
- Accumulation of Lewy bodies in dopamine neurons of the substantia nigra 
pars compacta [75]
- Hyperphosphorylation of tau protein causes accumulation of neurofibrillary 
tangles [76]
4.3.2 Protein degradation pathways
- Ubiquitin-proteasome system (UPS): It is responsible for the degradation of 
misfolded or damaged proteins in the cytosol, nucleus, or endoplasmic reticulum 
(ER) [77]. Impairment in this system leads to aggregation of misfolded amyloid 
proteins (Lewy bodies) [78]. Other proteins like UCH-L1 and Parkin are involved in 
the degradation of misfolded α-synuclein [79]
- Chaperones (heat shock proteins/HSP): Chaperones undergo dysfunction-
ing in PD, as they play a vital role in cell-defense mechanism involved in protein 
degradation and folding of proteins. Major HSPs involved are HSP 26, HSP40, HSP 
60, HSP 70, HSP 90, and HSP 100 [80]. HSPs aggregate with α-synuclein or tau 
protein and form insoluble structures resulting in reduced toxicity of α-synuclein or 
tau protein [81, 82]
- Autophagy-lysosomal pathway (ALP): It serves to clear Lewy bodies in PD act-
ing as an alternative clearance mechanism for proteins [83, 84]. Chaperone-mediated 
autophagy (CMA) helps in the degradation of α-synuclein by selectively translocat-
ing into lysosomes [83]. Therefore, dysfunctioning of CMA decreases the efficiency 
of α-synuclein, leading to excessive accumulation of this protein. This results in 
impaired neuronal activity as observed in PD [73, 85]. Failure of formation of 
autophagosome, its inability to bind with lysosomes due to deficiency of lysozymes, 
or dysfunction of HSP70 results in dysfunction of ALP in PD [73, 85] (Figure 4)
4.3.3 Damage to mitochondria and oxidative stress
- Abnormality of complex-I in mitochondria directly interferes with ATP pro-
duction in the cell, resulting in cell death [86]. Monoamines such as dopamine are 
cleaved by monoamine oxidase-B (MAO-B) and combined with oxygen-forming 
reactive oxygen species (ROS) [87]. Increased oxidative stress was observed in PD.
4.3.4 Genetic mutations
The most common genes related to PD are α-synuclein, DJ-1, PINK1, and Parkin 
[88] (Table 3).
4.4 Therapeutic approaches
4.4.1 Mitochondria-directed therapies
Administration of creatine increases tyrosine hydroxylase immunoreactive 
fiber density and soma size of dopaminergic neurons in mesencephalic cultures by 
protecting against neurotoxic insults induced by serum and glucose deprivation, 
MPP+, and 6-hydroxydopamine [33, 92]. It has been reported that dopamine loss 
was prevented by administration of creatine. In substantia nigra, creatine also 
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reduces loss of neuron in the mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP) [93].
CoQ10 protects against iron-induced apoptosis in dopaminergic neurons [94]. In 
vitro, CoQ10 exerts anti-amyloidogenic effects by disrupting preformed amyloid-β 
fibrils [95].
SS peptides (Szeto Schiller) act as antioxidants that target mitochondria in an 
independent manner. In mice, reports showed that SS-20 and SS-31 provide protec-
tion against MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) neurotoxicity. 
SS-31 provides protection against dopamine loss in the striatum. In substantia 
nigra, SS-31 also provides protection against the loss of tyrosine hydroxylase 
immunoreactive neurons. In MPTP-treated mice, SS-20 provides potential neuronal 
protection on dopaminergic neurons in PD [96].
4.4.2 Stem cell therapy
In the first trial of cell-based therapy, post-mitotic dopamine neuroblasts iso-
lated from human embryonic mesencephalic tissue have been successfully grafted 
in PD patients [97]. It has been confirmed through increase in 18F-dopa intake, 
Figure 4. 
Molecular mechanism of PD.
Genes Dysfunction References
α-synuclein Aggregation of misfolded amyloid proteins [89]
Parkin Aggregation of misfolded amyloid proteins within SNpc [89]
DJ-1 (PARK7) Activities like transcriptional regulation, antioxidants, chaperone, and 
protease are dysregulated
[90]
PINK1 
(PARK6)
Mitochondrial dysfunctioning
Degeneration of substantia nigra neuron
[91]
Table 3. 
Specific gene mutations and their dysfunction involved in the development of PD.
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detected through positron emission tomography (PET) [98, 99]. The grafts restore 
dopamine release. Disadvantages of this therapy are limited tissue availability and 
grafts standardization.
Recently, researchers have shed light on stem cell therapy. The production of 
dopamine neuroblasts from stem cells for transplantation in PD patients has been 
focused on. The aim was to release dopamine in a stable manner and exhibit the 
electrophysiological, molecular, and morphological properties of substantia nigra 
neurons [100, 101]. In clinical trials, it has been found that dopaminergic cells 
derived from embryonic stem cells can survive and reverse behavioral deficits after 
transplantation in PD animal models [102, 103].
4.4.3 Epigenetic modulators
In sporadic PD patients, there is an increased α-synuclein expression in dopami-
nergic neurons, which is linked with α-synuclein hypomethylation [104]. In familial 
PD patients, decreased histone acetylation is linked with increased α-synuclein lev-
els [105]. In vitro model, mutation in α-synuclein leads to increased histone acetyla-
tion mediated through HDAC Sirt2. Treatment of Sirt2 siRNA resulted in decreased 
α-synuclein-mediated toxicity [106]. Administration of levodopa elevated the 
dopamine level, which partially showed decreased symptoms of PD.  
It is correlated with deacetylation of H4K5, K12, and K16 [107].
4.4.4 Mitochondrial dynamics modulators
Recombinant adeno-associated virus expressing the dominant negative Drp1 
(dynamin-related protein 1) mutant or Mdivi-1, a small molecular inhibitor of 
Drp1, has been reported to inhibit mitochondrial fragmentation, restore dopamine 
release, and prevent dopamine neuron loss in PD animal models [108].
Activation of DRP1-mediated mitochondrial fission is an important contribut-
ing factor in the progression of PD. Neurons lacking PINK or Parkin accumulate 
DRP1, resulting in excessive mitochondrial fission, increased oxidative stress, and 
reduced ATP production [108, 109]. These defects can be reversed by the inhibition 
of mitochondrial fission with the use of mdivi-1, an inhibitor of the DRP1 pathway, 
or by overexpression of MFN2 (Mitofusin 2) or OPA1 (Optic atrophy protein 1) 
[109, 110].
In vitro models of glutamate-toxicity or OGD (oxygen-glucose deprivation) in 
mouse hippocampal neurons or in vivo mouse models of transient focal ischemia 
can be protected from enhanced mitochondrial fission and apoptosis by DRP1 
knockdown or mdivi-1 inhibition [111, 112].
5. Conclusion
The recent advancements in the field of neurodegenerative diseases like AD and 
PD are based on targeting the degenerative progressions that lead to the death of 
neurons. The death of neurons leads to irreversible neuropathological conditions, 
making it difficult to be functional in humans. Because of the intricacy involved 
in respective neurodegenerative diseases, researchers have identified few potential 
biomarkers. At present, many therapeutic approaches have been suggested to treat 
the symptoms of both neurodegenerative diseases. Yet there exists a lacuna for the 
effective therapies. Hence, few therapeutic approaches like mitochondria-targeted 
antioxidant therapy, mitochondrial dynamics modulators, epigenetic modulators, 
and neural stem cell therapy may prove to have a potential in treating AD and PD.
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